NASDAQ$TCMD

Tactile Systems Technology Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Reported financial results for the second quarter ended June 30, 2021.

Tactile Systems Technology, Inc. reported a 45% increase in total revenue year-over-year, reaching $51.1 million. The company also reported a net income of $1.3 million, a significant improvement compared to the net loss of $13.9 million in the second quarter of 2020.

  • Total revenue increased 45% year-over-year to $51.1 million.
  • Operating loss decreased to $0.1 million, compared to $8.0 million in the second quarter of 2020.
  • Net income reached $1.3 million, a significant improvement from a net loss of $13.9 million in the prior year.
  • Cash and cash equivalents totaled $49.0 million as of June 30, 2021.

Headline financials

Total Revenue

$51.1M

Previous: $35.1M+45.4%
EPS (adj)

$0.07

Previous: -$0.51+113.7%
Total revenue growth

45.0%

No prior period
Capital Expenditures

-$603K

Previous: -$660K+8.6%
Free Cash Flow

$702K

Previous: -$14.5M+104.8%
Net Income

$1.31M

Previous: -$13.9M+109.4%
Operating Income

-$76K

Previous: -$7.96M+99.0%
Gross Profit

$36.2M

Previous: $24.9M+45.3%
Cash & Equivalents

$49M

Previous: $31.3M+56.3%
Total Assets

$182M

Previous: $142M+28.3%
Stock-Based Comp

$2.66M

Previous: $2.4M+10.9%

Revenue & EPS history

Tactile Systems · Revenue · Quarterly

$51.1M

Q2 2021+45.4%vs Q2 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Tactile Systems · $68.3M total across 2 segments · Q2 2023

  • Lymphedema products
    $60M+16.2%
  • Airway clearance products
    $8.34M+4.1%

Forward guidance

The Company now expects full year 2021 total revenue in the range of $216.3 million to $224.5 million, representing growth of approximately 16% to 20% year-over-year, compared to total revenue of $187.1 million in 2020.

Tailwinds

  • Team's solid execution
  • Continued recovery within the broader U.S. healthcare environment
  • Notable improvements in the number of patients seeking care
  • Improvements in clinic capacity
  • Continued execution and improvements in the operating environment

Headwinds

  • Business continued to face headwinds during the second quarter from COVID-related restrictions adopted by healthcare facilities
  • Impacts of the COVID-19 pandemic on the Company’s business, financial condition and results of operations
  • The course of the COVID-19 pandemic and its impact on general economic, business and market conditions
  • The Company’s inability to execute on its plans to respond to the COVID-19 pandemic
  • The adequacy of the Company’s liquidity to pursue its business objectives

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+3.1%

Avg return

Earnings day

+3.6%

Avg return

5 days after

+5.9%

Avg return

30 days after

64%

29 / 45 earnings

Positive

+40.6%

Q3 2025

Best reaction

-29.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+7.2%+14.5%+12.2%
Q4 2025+17.4%+2.2%-7.0%
Q3 2025+40.6%+57.6%+70.0%
Q1 2025-29.0%-31.6%-27.5%
Q4 2024-13.3%-16.6%-25.6%
Q3 2024-8.6%+2.2%+29.5%
Q2 2024+7.2%+8.6%+8.4%
Q1 2024+1.1%-2.6%-15.2%
Q4 2023-5.4%+8.0%+12.6%
Q3 2023-22.8%-16.9%+1.3%
Q2 2023-14.7%-10.2%-10.1%
Q1 2023+14.0%+15.7%+29.6%
Q4 2022+2.4%+7.6%+13.5%
Q3 2022+17.8%+27.5%+49.9%
Q2 2022+18.2%+15.0%+6.5%
Q1 2022+2.4%-22.9%-41.8%
Q4 2021+7.3%+29.9%+30.6%
Q3 2021-22.9%-22.1%-44.1%
Q2 2021-9.1%-10.8%-8.6%
Q1 2021-7.5%-2.4%-9.0%
Q4 2020-10.4%-15.0%-13.7%
Q3 2020+5.4%-2.7%+14.4%
Q2 2020-13.3%-8.4%-9.9%
Q1 2020-1.0%+3.2%+4.8%
Q4 2019-2.8%-6.3%-28.2%
Q3 2019+7.8%+12.4%+35.8%
Q2 2019-9.6%-7.6%-11.3%
Q1 2019+4.5%+4.0%-4.6%
Q4 2018+0.4%+2.9%-27.5%
Q3 2018-7.9%-5.6%-18.2%
Q2 2018+13.4%+12.4%+37.6%
Q1 2018+20.0%+26.8%+41.2%
Q4 2017+7.8%+1.6%-0.8%
Q3 2017-10.4%-7.6%-1.1%
Q2 2017+17.4%+7.7%+19.3%
Q1 2016+13.9%+22.1%+31.1%
Q1 2017+13.9%+22.1%+31.1%
Q1 2015+17.7%+10.2%+6.1%
Q4 2016+17.7%+10.2%+6.1%
Q4 2014+17.7%+10.2%+6.1%
Q3 2015+7.6%+2.1%-11.1%
Q3 2016+7.6%+2.1%-11.1%
Q4 2015+6.8%+3.9%+31.8%
Q2 2016+6.8%+3.9%+31.8%
Q2 2015+6.8%+3.9%+31.8%
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro